Curative treatment of gastric cancer: Towards a multidisciplinary approach?

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 1, 2003, Pages 59-100

  Roth, Arnaud D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adjuvant therapy; Chemotherapy; Gastric cancer; Multidisciplinary treatment; Neoadjuvant therapy; Radiotherapy; Surgery

Indexed keywords

APC PROTEIN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HERMES ANTIGEN; IRINOTECAN; LOMUSTINE; MARIMASTAT; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; THYMIDYLATE SYNTHASE; TRIAZINATE; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VASCULOTROPIN;

ALOPECIA; ANAPHYLAXIS; ANEMIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTRECTOMY; GENE MUTATION; HELICOBACTER INFECTION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; NUTRITIONAL STATUS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0037379539     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00160-9     Document Type: Review

References (514)

1. Parkin D.M. Epidemiology of cancer global patterns and trends. Toxicol. Lett. 102-103:1998;227-234.
2. Howson C.P., Hiyama T., Wynder E.L. The decline in gastric cancer epidemiology of an unplanned triumph. Epidemiol. Rev. 8:1986;1-27.
3. Neugut A.I., Hayek M., Howe G. Epidemiology of gastric cancer. Semin. Oncol. 23:1996;281-291.
4. Correa P. The epidemiology of gastric cancer. World J. Surg. 15:1991;228-234.
5. Pinheiro P.S., van der Heijden L.H., Coebergh J.W. Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Lauren type and subsite. Int. J. Cancer. 84:1999;28-32.
6. Devesa S.S., Blot W.J., Fraumeni J.F. Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:1998;2049-2053.
7. Dolan K., et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br. J. Cancer. 80:1999;834-842.
8. Fernandez-Botran R. Soluble cytokine receptors: Their role in immunoregulation. FASEB J. 5:1991;2567-2574.
9. Powell S.M., et al. APC mutations occur early during colorectal tumorigenesis. Nature. 359:1992;235-237.
10. Vogelstein B., et al. Genetic alterations during colorectal-tumor development. New Eng. J. Med. 319:1988;525-532.
11. Tamura G. Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. Pathol. Int. 46:1996;834-841.
12. Correa P., et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. T. 50:1990;4737-4740.
13. Rugge M., et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology. 107:1994;1288-1296.
14. Weinstein W.M., Goldstein N.S. Gastric dysplasia and its management. Gastroenterology. 107:1994;1543-1545.
15. Dijkhuizen S.M., et al. Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential. Gastroenterology. 112:1997;561-566.
16. Shiao Y.H., et al. Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a high-risk area of central Italy. Carcinogenesis. 19:1998;2145-2149.
17. Correa P., Shiao Y.H. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 54:1994;1941s-1943s.
18. Gong C., et al. KRAS mutations predict progression of preneoplastic gastric lesions. Cancer Epidemiol. Biomarkers Prev. 8:1999;167-171.
19. Shiao Y.H., et al. p53 alteration in gastric precancerous lesions. Am. J. Pathol. 144:1994;511-517.
20. Hongyo T., et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 55:1995;2665-2672.
21. Fedriga R., et al. Relation between food habits and p53 mutational spectrum in gastric cancer patients. Int. J. Oncol. 17:2000;127-133.
22. Strickler J.G., et al. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res. 54:1994;4750-4755.
23. Chong J.M., et al. Microsatellite instability in the progression of gastric carcinoma. Cancer Res. 54:1994;4595-4597.
24. Kobayashi K., et al. Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach. Eur. J. Cancer. 36:2000;1113-1119.
25. Palli D., et al. Red meat, family history, and increased risk of gastric cancer with microsatellite instability. Cancer Res. 61:(14):2001;5415-5419.
26. Nogueira A.M., et al. Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer. 86:1999;1649-1656.
27. Kashiwagi K., et al. Clinical usefulness of Microsatellite instability for the prediction of gastric adenoma or adenocarcinoma in patients with chronic gastritis. Br. J. Cancer. 82:2000;1814-1818.
28. Kim M.S., et al. Microsatellite instability in the adenoma-carcinoma sequence of the stomach. AACR Proc. 41:2000;510-514.
29. Leung W.K., et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am. J. Pathol. 156:(2):2000;537-543.
30. La Vecchia C., et al. Family history and the risk of stomach and colorectal cancer. Cancer. 70:1992;50-55.
31. Gayther S.A., et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 58:1998;4086-4089.
32. Zanghieri G., et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer. 66:1990;2047-2051.
33. Lin K.M., et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J. Gastrointest. Surg. 2:1998;67-71.
34. Vasen H.F., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 110:1996;1020-1027.
35. Akiyama Y., et al. Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers. Jpn. J. Cancer Res. 87:1996;595-601.
36. Keller G., et al. Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. Int. J. Cancer. 68:1996;571-576.
37. Caldas C., et al. Familial gastric cancer, overview and guidelines for management. J. Med. Genet. 36:1999;873-880.
38. Shinmura K., et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis. 20:1999;1127-1131.
39. Yanagisawa Y., et al. Methylation of the hMLH1 promoter in familial gastric cancer with microsatellite instability. Int. J. Cancer. 85:2000;50-53.
40. Keller G., et al. Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history. Am. J. Pathol. 152:1998;1281-1289.
41. Wallace M.H., Phillips R.K. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br. J. Surg. 85:1998;742-750.
42. Enomoto M., et al. The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn. J. Clin. Oncol. 30:2000;82-88.
43. Jones T.R., Nance F.C. Periampullary malignancy in Gardner's syndrome. Ann. Surg. 185:1977;565-573.
44. Lillemoe K., Imbembo A.L. Malignant neoplasms of the duodenum. Surg. Gynecol. Obstet. 150:1980;822-826.
45. Hizawa K., et al. Juvenile polyposis of the stomach: clinicopathological features and its malignant potential. J. Clin. Pathol. 50:1997;771-774.
46. Hofgartner W.T., et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am. J. Gastroenterol. 94:1999;2275-2281.
47. Varley J.M., et al. An extended Li-Fraumeni kindred with gastric carcinoma andacodon 175 mutation in TP53. J. Med. Genet. 32:1995;942-945.
48. Sugano K., et al. Germline p53 mutation in a case of Li-Fraumeni syndrome presenting gastric cancer. Jpn. J. Clin. Oncol. 29:1999;513-516.
49. Guilford P., et al. E-cadherin germline mutations in familial gastric cancer. Nature. 392:1998;402-405.
50. Richards F.M., et al. Germline E-cadherin gene (CDH1) mutations predispose tc familial gastric cancer and colorectal cancer. Hurn. Mol. Genet. 8:1999;607-610.
51. Keller G., et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am. J. Pathol. 155:1999;337-342.
52. Dussaulx-Garin L., et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur. J. Gastroenterol. Hepatol. 13:(6):2001;711-715.
53. Lewis F.R., et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 130:(4):2001;612-619.
54. Correa P. A human model of gastric carcinogenesis. Cancer Res. 48:1988;3554-3560.
55. Boeing H., et al. Case-control study on stomach cancer in Germany. Int. J. Cancer. 47:1991;858-864.
56. Palli D. Epidemiology of gastric cancer an evaluation of available evidence. J. Gastroenterol. 35:(Suppl 12):2000;84-89.
57. Chyou P.H., et al. A case-cohort study of diet and stomach cancer. Cancer Res. 50:1990;7501-7504.
58. Blot W.J., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 85:1993;1483-1492.
59. Benner S.E., Hong W.K. Clinical chemoprevention: developing a cancer prevention strategy. J. Natl. Cancer Inst. 85:1993;1446-1447.
60. Coggon D., Osmond C., Barker D.J. Stomach cancer and migration within England and Wales. Br. J. Cancer. 61:1990;573-574.
61. Wu-Williams A.H., Yu M.C., Mack T.M. Lifestyle, workplace, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res. 50:1990;2569-2576.
62. McLaughlin J.K., et al. Stomach cancer and cigarette smoking among U.S. veterans, 1954-1980. Cancer Res. 50:1990;3804.
63. Hansson L.E., et al. Tobacco, alcohol and the risk of gastric cancer. A population-based case-control study in Sweden. Int. J. Cancer. 57:1994;26-31.
64. Nomura A., et al. A prospective study of stomach cancer and its relation to diet, cigarettes, and alcohol consumption. Cancer Res. 50:1990;627-631.
65. Clark G.W., et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia. Arch. Surg. 129:1994;609-614.
66. Chow W.H., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 90:1998;150-155.
67. Gammon M.D., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 89:1997;1277-1284.
68. Zhang Z.F., Kurtz R.C., Marshall J.R. Cigarette smoking and esophageal and gastric cardia adenocarcinoma. J. Natl. Cancer Inst. 89:1997;1247-1249.
69. Ricaurte O., et al. Helicobacter pylori infection in patients with Barrett's oesophagus: a prospective immunohistochemical study. J. Clin. Pathol. 49:1996;176-177.
70. Peek R.M. Jr, et al. Hole of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int. J. Cancer. 82:1999;520-524.
71. Scheiman J.M., Cutler A.F. Helicobacter pylori and gastric cancer. Am. J. Med. 106:1999;222-226.
72. Ernst P. Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment. Pharmacol. Ther. 13:(Suppl 1):1999;13-18.
73. Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology. 113:1997;1983-1991.
74. Smoot D.T., et al. H. Pylori induces 8-OH deoxyguanosine adducts in gastric epithelial ceils in vitro. AACR Proc. 41:2000;540.
75. Nyren O. Is Helicobacter pylori really the cause of gastric cancer? Semin. Cancer Biol. 8:1998;275-283.
76. Danesh J. Helicobacter pylori and gastric cancer time for mega-trials? Br. J. Cancer. 80:1999;927-929.
77. Parsonnet J., et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 40:1997;297-301.
78. Blaser M.J., et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55:1995;2111-2115.
79. Deguchi R., et al. Association between CagA+ Helicobacter pylori infection and p53, bax and transforming growth factor-beta-RII gene mutations in gastric cancer patients. Int. J. Cancer. 91:(4):2001;481-485.
80. Palli D. Gastric cancer and Helicobacter pylori: a critical evaluation of the epidemiological evidence. Helicobacter. 2:(Suppl 1):1997;S50-S55.
81. El-Omar E.M., et al. Helicobacter pylori infection and abnormalities of add secretion in patients with duodenal ulcer disease. Gastroenterology. 109:1995;681-691.
82. El-Omar E.M., et al. Helicobacter pylori infection and chronic gastric add hyposecretion. Gastroenterology. 113:1997;15-24.
83. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
84. Wallace J.L., et al. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am. J. Physiol. 261:1991;G559-G564.
85. Beales I.L., Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit add secretion in cultured rabbit parietal cells by multiple pathways. Gut. 42:1998;227-234.
86. El-Omar E.M., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:2000;398-402.
87. El-Omar E.M., et al. The role of interleukin 1 polymorphisms in the pathogenesis of gastric cancer. AACR. Proceedings. 41:2000;550-552.
88. Magnusson P.K.E., et al. Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res. 61:(6):2001;2684-2689.
89. Blaser M.J. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J. Infect.Dis. 179:1999;1523-1530.
90. Blaser M.J. Linking Helicobacter pylori to gastric cancer. Nat. Med. 6:(4):2000;376-377.
91. Feldman R.A. Review article: would eradication of Helicobacter pylori infection reduce the risk of gastric cancer. Aliment. Pharrnacol. Ther. 15:(Suppl 1):2001;2-5.
92. Graham D.Y. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet. 350:1997;70-71.
93. Blaser M.J. Not all Helicobacter pylori strains are created equal: should all be eliminated. Lancet. 349:1997;1020-1022.
94. Fleming I.D., et al. Manual for staging of cancer. Fifth edn: 1997;Lippincott, Philadelphia.
95. Sobin L.H., Wittekind C.H. International Union against Cancer. TNM classification of malignant tumors. Fifth edn: 1997;Wiley, New York.
96. Japanese Research Society for Gastric Cancer, Japanese classification of gastric carcinoma, 1 ed. 1995, Tokyo: Kanehara & Co, Ltd.
97. Fujii K., et al. Clinical evaluation of lymph node metastasis in gastric cancer defined by the fifth edition of the TNM classification in comparison with the Japanese system. Br. J. Surg. 86:1999;685-689.
98. Hayashi H., et al. Superiority of a new UICC-TNM staging system for gastric carcinoma. Surgery. 127:2000;129-135.
99. Borchard F. Classification of gastric carcinoma. Hepatogastroenterology. 37:1990;223-232.
100. Lauren P. The two histological main types of gastric carcinoma. Acta. Pathol. Microbiol. Scand. 64:1965;31-49.
101. Oota K, Sobin LH. Histological typing of gastric and oesophageal tumors, in international histological classification of tumors, WHO, Editor. 1977, WHO: Geneva.
102. Cimerman M., et al. Comparison of Lauren's, Ming's and WHO histological classifications of gastric cancer as a prognostic factor for operated patients. Int. Surg. 79:1994;27-32.
103. Setala L.P., et al. Prognostic factors in gastric cancer: the value of vascular invasion mitotic rate and lymphoplasmacytic infiltration. Br. J. Cancer. 74:1996;766-772.
104. Yu C.C., et al. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. Br. J. Cancer. 71:1995;1106-1110.
105. Wu C.W., et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosislymph node metastasis and poorly differentiated nuclear grade. Br. J. Cancer. 80:1999;483-488.
106. Maehara Y., et al. Prognostic value of p53 protein expression for patients with gastric cancer-a multivariate analysis. Br. J. Cancer. 79:1999;1255-1261.
107. Maeda K., et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 55:1998;594-599.
108. Fonseca L., et al. p53 detection as a prognostic factor in early gastric cancer. Oncology. 51:1994;485-490.
109. Joypaul B.V., et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br. J. Cancer. 69:1994;943-946.
110. Martin H.M., et al. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer. 50:1992;859-862.
111. Aizawa K., et al. Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int. J. Oncol. 14:1999;85-91.
112. Polkowski W., et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 6:1999;290-297.
113. Nakajtma M., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 85:1999;1894-1902.
114. Heiss M.M., et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type piasminogen activator system. J. Clin. Oncol. 13:1995;2084-2093.
115. Heiss M.M., et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med. 1:1995;1035-1039.
116. Yonemura Y., et al. Prediction of lymph node metastasis and prognosis from the assay of the expression of proliferating cell nuclear antigen and DNA ploidy in gastric cancer. Oncology. 51:1994;251-257.
117. Muller W., et al. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J. Pathol. 183:1997;222-227.
118. Yoo C.H., et al. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage II and stage IIIA gastric carcinoma. J. Surg. Oncol. 71:1999;22-28.
119. Metzger R., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16:1998;309-316.
120. Lenz H.J., et al. Thymidylate synthase mRNA level in adenocardnoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14:1996;176-182.
121. Hundahl S.A., et al. The National Cancer Data Base report on gastric carcinoma. Cancer. 80:1997;2333-2341.
122. Hansson L.E., Sparen P., Nyren O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann. Surg. 230:1999;162-169.
123. Faivre J., et al. Survival of patients with oesophageal and gastric cancers in Europe. Eur. J. Cancer. 34:1998;2167-2175.
124. Roder J.D., et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer. 72:1992;2089-2097.
125. Webb A., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15:1997;261-267.
126. Vanhoefer U., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 18:2000;2648-2657.
127. Roth A.D., et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. 11:2000;301-306.
128. Nakamura K., et al. Pathology and prognosis of gastric carcinoma. Findings in 10 000 patients who underwent primary gastrectomy. Cancer. 70:1992;1030-1037.
129. Fuchs C.S., Mayer R.J. Gastric carcinoma. New Engl. J. Med. 333:1995;32-41.
130. Brennan M.F., Karpeh M.S. Jr. Surgery for gastric cancer: the American view. Semin. Oncol. 23:1996;352-359.
131. McNeer G., et al. A critical evaluation of subtotal gastrectomy for cure of cancer of the stomach. Ann. Chir. 134:1951;2-7.
132. Arhelger S.W., Lober P.M., Wangensteem O.H. Dissection of the hepatic pedicle and retropancreaticoduodenal area for cancer of the stomach. Surgery. 38:1955;675-678.
133. Longmire W.P. Total gastrectomy for carcinoma of the stomach. Surg. Gynecol. Obstet. 84:1947;21-25.
134. Lahey F.H. Total gastrectomy for all patients with operable gastric cancer of the stomach. Surg. Gynecol. Obstet. 90:1950;246-249.
135. McCulloch P. Description of the Japanese method of radical gastrectomy. Ann. R. Coll. Surg. Engl. 76:1994;110-114.
136. Lortat-Jacob J., et al. Value of total gastrectomy for treatment of cancers of the stomach. Study of 482 radical operations. Chirurgie. 101:1975;59-67.
137. McNeer G., et al. Elective total gastrectomy for cancer of the stomach: end results. Ann. Surg. 180:1974;252-256.
138. Shiu M.H., et al. Selection of operative procedure for adenocarcinoma of the midstomach. Twenty year's experience with implications for future treatment strategy. Ann. Surg. 192:1980;730-737.
139. Allum W.H., et al. Gastric cancer: a 25-year review. Br. J. Surg. 76:1989;535-540.
140. Akoh J.A., Maclntyre I.M. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1979. Br. J. Surg. 79:1992;293-299.
141. Wu C.W., et al. Morbidity and mortality after radical gastrectomy for patients with carcinoma of the stomach. J. Ann. Coll. Surg. 181:1995;26-32.
142. Maruyama K., Okabayashi K., Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J. Surg. 11:1987;418-425.
143. Korenaga D., et al. Trends in survival rates in Japanese patients with advanced carcinoma of the stomach. Surg. Gynecol. Obstet. 174:1992;387-393.
144. Wanebo H.J., et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 218:1993;583-592.
145. Smith J.W., et al. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch. Surg. 126:1991;1469-1473.
146. Lawrence W. Jr, et al. The National Cancer Data Base report on gastric cancer. Cancer. 75:1995;1734-1744.
147. Heberer G., et al. Results of gastric resection for carcinoma of the stomach: the European experience. World J. Surg. 12:1988;374-381.
148. Launois B., et al. Management of cancer of the stomach: total gastrectomy versus sub-total gastrectomy. Hepatogastroenterology. 38:1991;45-52.
149. Le Treut Y.P., et al. Cancer of the gastric antrum. What can be expected from the systematic enlargement of the excision? Retrospective study of 73 cases. Press Med. 14:1985;1319-1327.
150. Gennari L., et al. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. Br. J. Surg. 73:1986;534-538.
151. Gouzi J.L., et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann. Surg. 209:1989;162-166.
152. Bozzetti F., et al. Subtotal versus total gastrectomy for gastric cancer five-year survival rates in a multicenter randomized Italian trial. Ann. Surg. 230:1999;170-178.
153. Davies J., et al. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J. Surg. 22:1998;1048-1055.
154. Svedlund J., et al. Long term consequences of gastrectomy for patient's quality of life: the impact of reconstructive techniques. Am. J. Gastroenterol. 94:1999;438-445.
155. Balfour D.C. Factors influencing the life expectancy of patients operated on for gastric ulcer. Ann. Surg. 76:1922;405-408.
156. Saegesser F., James D. Cancer of the gastric stump after partial gastrectomy (Billroth II principle) for ulcer. Cancer. 29:1972;1150-1159.
157. Pickford I.R., et al. Endoscopic examination of the gastric remnant 31-39 years after subtotal gastrectomy for peptic ulcer. Gut. 25:1984;393-397.
158. Offerhaus G.J., et al. Mortality caused by stomach cancer after remote partial gastrectomy for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients. Gut. 29:1988;1588-1590.
159. Chen C.N., et al. Clinicopathologic characteristics and prognosis of gastric stump cancer. J. Clin. Gastroenterol. 23:1996;251-255.
160. Kuwahara A., Saito T., Kobayashi M. Bile acids promote carcinogenesis in the remnant stomach of rats. J. Cancer Res. Clin. Oncol. 115:1989;423-428.
161. Langhans P., et al. Gastric stump carcinoma-new aspects deduced from experimental results. Scand. J. Gastroenterol. Suppl. 67:1981;161-164.
162. Reed P.I., et al. The influence of enterogastric reflux on gastric juice bacterial growth, nitrite and N-nitroso compound concentrations following gastric surgery. Scand. J. Gastroenterol. Suppl. 92:1984;232-234.
163. Espat N.J., Karpeh M. Reconstruction following total gastrectomy: a review and summary of the randomized prospective clinical trials. Surg. Oncol. 7:1998;65-69.
164. Safatle-Ribeiro A.V., et al. Morphologic histologic and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer. 78:1996;2288-2299.
165. Wisbeck W.M., Becher E.M., Russell A.H. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother. Oncol. 7:1986;13-18.
166. Greene F.L. Management of gastric remnant carcinoma based on the results of a 15-year endoscopic screening program. Ann. Surg. 223:1996;701-706.
167. McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results 1980-1985. Br. J. Surg. 81:1994;417-420.
168. Siewert J.R. The future of oesophageal and gastric surgery. Ann. Chir. Gynaecol. 85:1996;196-200.
169. Kockerling F., Reck T., Gall F.P. Extended gastrectomy: who benefits. World J. Surg. 19:1995;541-545.
170. Harrison L.E., Karpeh M.S., Brennan M.F. Total gastrectomy is not necessary for proximal gastric cancer. Surgery. 123:1998;127-130.
171. Isozaki H., et al. Proximal subtotal gastrectomy for the treatment of carcinoma of the upper third of the stomach: its indications based on lymph node metastasis and perigastric lymphatic flow. Surg. Today. 25:1995;21-26.
172. Bremers A.J., Rutgers E.J., Van de Velde C.J. Career surgery: the last 25 years. Cancer Treat. Rev. 25:1999;333-353.
173. Veronesi U., Zurrida S. Breast cancer surgery: a century after Halsted. J. Cancer Res. Clin. Oncol. 122:1996;74-77.
174. Winchester D.J., Menck H.R., Winchester D.P. The National Cancer Data Base report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer. 80:1997;162-167.
175. Posner M.C., Wolmark N. Indications for breast-preserving surgery and adjuvant therapy in early breast cancer. Int. Surg. 79:1994;43-47.
176. Wolmark N., Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Duke's B and C rectal carcinoma, A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Ann. Surg. 204:1986;480-489.
177. Morrow M., Harris J.R., Schnitt S.J. Local control following breast-conserving surgery for invasive cancer results of clinical trials. J. Natl. Cancer Inst. 87:1995;1669-1673.
178. Rutqvist L.E. Radiation therapy as an adjunct to primary surgery in early stage breast cancer: biological and clinical rationale. Semin. Radiat. Oncol. 9:1999;217-222.
179. Leedham B., Ganz P.A. Psychosocial concerns and quality of life h breast cancer survivors. Cancer Invest. 17:1999;342-348.
180. Meyer H.J., Pichlmayr R. Patterns of Recurrence in relation to therapeutic strategy in gastric cancer. Scand. J. Gastroenterol. 22:1987;45-48.
181. Landry J., et al. Patterns of failure following curative resection of gastric carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;1357-1362.
182. Roukos D.H., Kappas A.M., Encke A. Extensive lymph-node dissection in gastric cancer is it of therapeutic value. Cancer Treat. Rev. 22:1996;247-252.
183. Roukos D.H. Extended lymphadenectomy in gastric cancer when, for whom and why. Ann. R. Coll. Surg. Engl. 80:1998;16-24.
184. Jessup J.M. Is bigger better. J. Clin. Oncol. 13:1995;5-7.
185. Lawrence W. Jr, Horsley J.S. Extended lymph node dissections for gastric cancer-is more better? [editorial]. J. Surg. Oncol. 61:1996;85-89.
186. Mine M., et al. End results of gastrectomy for gastric cancer: effect of extensive lymph node dissection. Surgery. 68:1970;753-758.
187. Kodama Y., et al. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J. Surg. 5:1981;241-248.
188. Kitamura K., et al. Analysis of lymph node metastasis in early gastric cancer: rationale of limited surgery. J. Surg. Oncol. 64:1997;42-47.
189. Maruyama K., et al. Surgical treatment for gastric cancer: the Japanese approach. Semin. Oncol. 23:1996;360-368.
190. Maeta M., et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery. 125:1999;325-331.
191. Yonemura Y., et al. Lymph node metastases from carcinoma of the gastric stump. Hepatogastroenterology. 41:1994;248-252.
192. Kaibara N., et al. Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer. Ann. J. Surg. 159:1990;218-221.
193. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn. J. Surg. 11:1981;127-139.
194. Yonemura Y., et al. Surgical results of performing R4 gastrectomy for gastric cancer located in the upper third of the stomach. Surg. Today. 24:1994;488-493.
195. Siewert J.R., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann. Surg. 228:1998;449-461.
196. Jatzko G.R., et al. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer. 76:1995;1302-1312.
197. Pacelli F., et al. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br. J. Surg. 80:1993;1153-1156.
198. Volpe C.M., et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinorna. J. Am. Coll. Surg. 181:1995;56-64.
199. Siewert J.R., et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br. J. Surg. 83:1996;1144-1147.
200. Jaehne J., et al. Lymphadenectomy in gastric carcinoma. A prospective and prognostic study. Arch. Surg. 127:1992;290-294.
201. Dent D.M., Madden M.V., Price S.K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J. Surg. 75:1988;110-112.
202. Robertson C.S., et al. A prospective randomized trial comparing P1 subtotal gastrectomy with R3 total gastrectomy for antrai cancer [see comments]. Ann. Surg. 220:1994;176-182.
203. Bonenkamp J.J., et al. Extended lymph-node dissection for gastric cancer. New Engl. J. Med. 340:1999;908-914.
204. Bonenkamp J.J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 345:1995;745-748.
205. Cuschieri A., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br. J. Cancer. 79:1999;1522-1530.
206. Cuschieri A., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer preliminary results of the MRC randomised controlled surgical trial. Lancet. 347:1996;995-999.
207. Okajima K., Isozaki H. Splenectomy for treatment of gastric cancer Japanese experience. World J. Surg. 19:1995;537-540.
208. Otsuji E., et al. End results of simultaneous splenectomy in patients undergoing total gastrectomy for gastric carcinoma. Surgery. 120:1996;40-44.
209. Brady M.S., et al. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch. Surg. 126:1991;359-364.
210. Sasako M., et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br. J. Surg. 82:1995;346-351.
211. Griffith J.P., et al. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 36:1995;684-690.
212. Maruyama K., et al. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J. Surg. 19:1995;532-536.
213. Maehara Y., et al. Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 67:1991;3006-3009.
214. Keller E., et al. Lymph node staging in 872 patients with carcinoma of the stomach and the presumed benefit of lymphadenectomy. J. Am. Coll. Surg. 178:1994;38-46.
215. Maruyama K., et al. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann. Surg. 210:1989;596-602.
216. Kodera Y., et al. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J. Surg. 21:1997;622-627.
217. Wanebo H.J., et al. Hole of Splenectomy in gastric cancer surgery: adverse effect of elective Splenectomy on longterm survival. J. Am. Coll. Surg. 185:1997;177-184.
218. Kasakura Y., et al. Is there a benefit of pancreaticosplenectomy with gastrectomy for advanced gastric cancer. Am. J. Surg. 179:(3):2000;237-242.
219. Sakarnoto J., Yasue M. Extensive tymphadenectomy for gastric cancer patients: what can the results of one trial tell us. Lancet. 345:1995;742-743.
220. Hundahl S.A., Stemmermann G.N., Oishi A. Racial factors cannot explain superior Japanese outcomes in stomach cancer. Arch. Surg. 131:1996;170-175.
221. Sano T., Martin I.G. Lymphadenectomy and pancreaticosplenectomy in gastric cancer surgery. Lancet. 348:1996;195-196.
222. Siewert J.R., et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br. J. Surg. 80:1993;1015-1018.
223. Sue-Ling H.M., Johnston D. D1 versus D2 dissection for gastric cancer. Lancet. 345:1995;1515-1516.
224. McCulloch P. D1 versus D2 dissection for gastric cancer. Lancet. 345:1995;1516-1517.
225. Feinstein A.R., Sosin D.M., Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New Engl. J. Med. 312:1985;1604-1608.
226. Bunt A.M., et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J. Clin. Oncol. 13:1995;19-25.
227. Roukos D., et al. Extended lymph node dissection in gastric cancer induces substantial stage migration and increases stage-specific survival without improvement of overall survival. J. Clin. Oncol. 14:1996;2408-2410.
228. Caldwell W.L. Lymphadenectomy for testicular tumors. J. Am. Med. Assoc. 218:1971;98.
229. Staubitz W.J. Surgical treatment of non-seminomatous germinal testes tumors. Recent Results Cancer Res. 218:1977;215-220.
230. Dononue J.P., Foster R.S. Hetroperitoneal lymphadenectomy h staging and treatment. The development of nerve-sparing techniques. Urol. Clin. North Am. 25:1998;461-468.
231. Bohlen D., et al. Long-term results following adjuvant chemotherapy h patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J. Urol. 161:1999;1148-1152.
232. Preiner J.L., Jewett M.A. Role for retroperitoneal lymphadenectomy for testis cancer. Curr. Opin. Urol. 9:1999;205-208.
233. Horwich A. Primary chemotherapy: how does it compare with surgery. Semin. Urol. Oncol. 14:1996;34-35.
234. Recht A. Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes. J. Surg. Oncol. 72:1999;184-192.
235. Morrow M. Axillary dissection: when and how radical. Semin. Surg. Oncol. 12:1996;321-327.
236. Folli S., et al. Early gastric cancer prognostic factors in 223 patients. Br. J. Surg. 82:1995;952-956.
237. Hallissey M.T., et al. Early detection of gastric cancer. Br. Med. J. 301:1990;513-515.
238. Hanazaki K., et al. Surgical treatment of gastric cancer detected by mass screening. Hepatogastroenterology. 44:1997;1126-1132.
239. Jentschura D., et al. Surgery for early gastric cancer, a European one-center experience. World J. Surg. 21:1997;845-848.
240. Iriyama K., et al. Is extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach. Arch. Surg. 124:1989;309-311.
241. Sindelar W.F., et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am. J. Surg. 165:1993;178-186.
242. Hanazaki K., et al. Clinicopathologic features of submucosal carcinoma of the stomach. J. Clin. Gastroenterol. 24:1997;150-155.
243. Hanazaki K., et al. Surgical outcome in early gastric cancer with lymph node metastasis. Hepatogastroenterology. 44:1997;907-911.
244. Hayes N., et al. Radical lymphadenectomy in the management of early gastric cancer. Br. J. Surg. 83:1996;1421-1423.
245. Yanai H., et al. Diagnostic utility of 20-megahertz linear endoscopic ultrasonography in early gastric cancer. Gastrointest. Endosc. 44:1996;29-33.
246. Akahoshi K., et al. Pre-operative TN staging of gastric cancer using a 15 MHz ultrasound miniprobe. Br. J. Radiol. 70:1997;703-707.
247. Akahoshi K., et al. Endoscopic ultrasonography: a promising method for assessing the prospects of endoscopic mucosal resection in early gastric cancer. Endoscopy. 29:1997;614-619.
248. Takeshita K., et al. Rational lymphadenectomy for early gastric cancer with submucosal invasion: a clinicopathological study. Surg. Today. 28:1998;580-586.
249. Sano T., Kobori O., Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br. J. Surg. 79:1992;241-244.
250. Averbach A.M., Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br. J. Surg. 83:1996;726-733.
251. Heslin M.J. Extended lymph node dissection in gastric cancer if a benefit exists, can it ever be proven. Ann. Surg. Oncol. 7:(10):2000;715-716.
252. Macdonald J.S., et al. 5-fluorouradl, adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 44:1979;42-47.
253. Cunningham D., et al. Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin-C. Br. J. Surg. 71:1984;673-676.
254. Haim N., et al. Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin and mitomycin C (FAM). Cancer Chemother. Pharmacol. 8:1982;277-280.
255. Haim N., et al. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin) and mitomycin C (modified FAM). Cancer. 54:1984;1999-2002.
256. Macdonald J.S., Gohmann J.J. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin. Oncol. 15:1988;42-49.
257. Douglass H.O. Jr, et al. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J. Clin. Oncol. 2:1984;1372-1381.
258. Panettiere F.J., et al. Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. J. Clin. Oncol. 2:1984;420-424.
259. Wils J.A., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-A step ahead in the treatment of advanced gastric cancer A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9:1991;827-831.
260. Cullinan S.A., et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J. Clin. Oncol. 12:1994;412-416.
261. Lacave A., et al. An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil and adriamycin in advanced gastric cancer. J. Clin. Oncol. 5:1987;1387-1393.
262. Wils J., et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J. Clin. Oncol. 4:1986;1799-1803.
263. Murad A.M., et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 72:1993;37-41.
264. Leichman L., Berry B.T. Cisplatin therapy for adenocarcinoma of the stomach. Semin. Oncol. 18:(Suppl 3):1991;25-33.
265. Scanlon K.J., et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA. 83:1986;8923-8925.
266. Aisner J., Abrams J. Cisplatin for small-cell lung cancer. Semin. Oncol. 16:1989;2-9.
267. Phillips N.C., Lauper R.D. Review of etoposide. Clin. Pharm. 2:1983;112-119.
268. Wilke H., et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer a phase II study with etoposide, doxorubicin and cisplatin. J. Clin. Oncol. 7:1989;1318-1326.
269. Wilke H., et al. Etoposide, folinic acid and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother. Pharmacol. 29:1991;83-84.
270. Ychou M., et al. A phase II study of 5-fluorouracil leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur. J. Cancer. 32A:1996;1933-1937.
271. Preusser P., Wilke H., Achterrath W. Phase II study with the combination etoposide, doxorubicin and ciplatin in advanced measurable gastric carcinoma. J. Clin. Oncol. 7:1989;1310-1317.
272. Cocconi G., et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. 12:1994;2687-2693.
273. Kim N.K., et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 71:1993;3813-3818.
274. Kelsen D., et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. 10:1992;541-548.
275. O'Connell M.J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited. J. Clin. Oncol. 10:1992;515-516.
276. Lokich J., et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer. 48:1981;2565-2568.
277. Hryniuk W.M., Goodyear M. The calculation of received dose intensity. J. Clin. Oncol. 8:1990;1935-1937.
278. Drewinko B., Yang L.Y. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat. Rep. 69:1985;1391-1398.
279. Pinedo K.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
280. Sobrero A.F., Aschele C., Bertino J.R. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15:1997;368-381.
281. Lokich J.J., et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 7:1989;425-432.
282. Cancer, M.-a.G.I, Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 1998 16(1): 301-308.
283. Findlay M., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and dsplatinin combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 5:1994;609-616.
284. Bamias A., et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life and survival. Cancer. 77:1996;1978-1985.
285. Zaniboni A., et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 76:1995;1694-1699.
286. Young R.C. Mechanisms to improve chemotherapy effectiveness. Cancer. 65:1990;815-822.
287. Cascinu S., et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer. J. Clin. Oncol. 15:1997;3313-3319.
288. Chi K.H., et al. Weekly etoposide, epirubicin, cisplatin 5-fiuorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. Br. J. Cancer. 77:1998;1984-1988.
289. Fuchs C.S. Chemotherapy for advanced gastric cancer: Where do we stand? J. Clin. Oncol. 15:1997;3299-3300.
290. Sakata Y., et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer. 34:1998;1715-1720.
291. Koizumi W., Ujiie S., Taguchi T. Gastric carcinoma: A phase II study of capecitabine with new dosing regimen in patients with advanced/metastatic gastric carcinoma. Eur. J. Cancer. 35:(suppl. 4):1999;S140-S148.
292. Louvet C., et al. Phase II trial of oxaliplatin (OXA) in combination with 5FU and foiinic acid (FA) -FOLFOX6 regimen- as first-line treatment for advanced or metastatic gastric cancer (A/MGC) patients. ASCO Proc. 19:2000;265a-2650.
293. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91:1981;479-487.
294. Schiff P.B., Horwitz S.B. Taxol assembles tubulin in the absence of exogenous guanosine 5′-trtphosphate or microtubule-associated proteins. Biochemistry. 20:1981;3247-3252.
295. Rowinsky E.K., Donehower R.C. Paditaxel (taxol). New Eng. J. Med. 332:1995;1004-1014.
296. Vokes E.E., et al. The role ofpaclitaxel in the treatment of head and neck cancer. Semin. Oncol. 22:1995;8-12.
297. Einzig A.I., et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest. New Drugs. 13:1995;223-227.
298. Ajani J.A., et al. Phase II study of Taxol In patients with advanced gastric carcinoma. Cancer J. Sci. Am. 4:1998;269-274.
299. Ohtsu A., et al. An early phase II study of a 3-h infusion of paclitaxel for advanced gastric cancer. Am. J. Clin. Oncol. 21:1998;416-419.
300. Cascinu S., et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisptatin, epidoxorubicin, 6S-leucovorln, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer. 78:1998;390-393.
301. Cascinu S., et al. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur. J. Cancer. 33:1997;1699-1702.
302. Bokemeyer C., et al. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs. 8:1997;396-399.
303. chun H., et al. Chemotherapy (CT) with cisplatin, fluorouracil (FU) and paclitaxel for adenocarcinoma (AC) of the stomach and gastroesophageal junction (GEJ). ASCO Proc. 18:1999;280a-2800.
304. Kim Y.H., et al. Paditaxel, 5-fluorouracil and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 85:1999;295-301.
305. Lokich J.J., et al. Combined paditaxel, cisplatin and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer. 85:1999;2347-2351.
306. Pazdur R., et al. The taxoids: paditaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev. 19:1993;351-386.
307. Gueritte-Voegelein F., et al. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:1991;992-998.
308. Ringel I., Horwitz S.B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl. Cancer Inst. 83:1991;288-291.
309. Verweij J., Clavel M., Chevalier B. Paditaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. 5:1994;495-505.
310. Bissery M.C., et al. Experimental antitumor activity of taxotere (HP 56976, NSC 628503) a taxol analogue. Cancer Res. 51:1991;4845-4852.
311. Catimel G., et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol. 5:1994;533-537.
312. Francis P.A., et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 12:1994;1232-1237.
313. Verweii J., et al. Phase II studies of docetaxei in the treatment of various solid tumours. Eur. J. Cancer. 31A:(suppl 4):1995;S21-S24.
314. Einzig A.I., et al. Phase II trial of docetaxei (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol. 13:1996;87-93.
315. Sulkes A., et al. Docetaxel (Taxotere) in advanced gastric cancer, results of a phase II clinical trial. Br. J. Cancer. 70:1994;380-383.
316. Mai M., et al. A late phase II clinical study of RP56976 (docetaxei) in patients with advanced or recurrent gastric cancer a cooperative study group trial (group B). Gan. To. Kagaku. Ryoho. 26:1999;487-496.
317. Schrijvers D., et al. Coping with toxicities of docetaxei (Taxotere). Ann. Oncol. 4:1993;610-611.
318. Verweij J., et al. A phase I study of Docetaxei and Cisplatin in patients with solid tumors. Ann. Oncol. 5:(Suppl 5):1994;500-504.
319. Roth A.D., et al. 5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastnc carcinoma (AGO). Eur. J. Cancer. 35:(suppl 4):1999;S130-S139.
320. Simon R., Wittes R.E., Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat. Rep. 69:1985;1375-1381.
321. Ajani J.A., et al. Multinational randomized phase II trial of docetaxei (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (Pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). ASCO Proc. 19:2000;247a-2470.
322. Ridwelski K., et al. Docetaxel-cisplatin, an effective palliative therapy concept in advanced gastric carcinoma. Eur. J. Cancer. 35:(suppl 4):1999;150-152.
323. Vanhoefer U., et al. Phase II study of docetaxei as second line chemotherapy (CT) in metastatic gastric cancer. ASCO Proc. 18:1999;303a-3030.
324. André T., et al. Docetaxel-epirubicine as second-line treatment for patients with advanced gastric cancer. ASCO Proc. 18:1999;277a.
325. Hsiang Y.H., et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxidty of camptothecin analogues. Cancer Res. 49:1989;4385-4389.
326. Chabot, GG, et al. Irinotecan pharmacokinetics. Bull Cancer. 1998. Spec No. pp. 11-20.
327. Tsuruo T., et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:1988;71-74.
328. Masuda N., et al. CPT-11; a new derivative of camptothedn for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1992;1225-1229.
329. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur. J. Cancer. 35:1999;371-379.
330. Fukuoka M., et al. A phase II study of CPT-11, a new derivative of camptothedn, for previously untreated non-small-cell lung cancer [see comments]. J. Clin. Oncol. 10:1992;16-20.
331. Christian M.C., Trimble E.L. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol. Oncol. 55:1994;S143-S150.
332. Verschraegen C.F., et al. Phase II study of irinotecan in prior chemotherapy-treated squamcus cell carcinoma of the cervix. J. Clin. Oncol. 15:1997;625-631.
333. Futatsuki K., et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Gan. To. Kagaku. Ryoho. 21:1994;1033-1038.
334. Kohne C.H., et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. ASCO Proc. 18:1999;258a-2580.
335. Shirao K., et al. Phase I-II study of irinotecan hydrochloride combined with cispiatin in patients with advanced gastric cancer. J. Clin. Oncol. 15:1997;921-927.
336. Boku N., et al. Phase II study of a combination of irinotecan and cispiatin against metastatic gastric cancer. J Clin. Oncol. 17:1999;319-323.
337. Ajani J.A., et al. Irinotecan plus cispiatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt). 15:(3 suppl 5):2001;52-54.
338. Yamao T., et al. Phase I/II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Eur. J. Cancer. 4:(suppl 4):1999;S140-S141.
339. Pozzo C., et al. Irinotecan (Iri) in combination with CDDP (C) or with 5-FUand folinic acid (FU/FA) is active in patients (pts) with avanced gastric or gastroesophageal junction adenocaroinoma (AGO). Ann. Oncol. 11:(suppl 4):2000;60-63.
340. Sato A., et al. Preliminary study of fortnightly irinotecan hydrochloride plus cispiatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother. Pharmacol. 47:(5):2001;380-384.
341. Matrisian L.M., et al. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:1990;121-125.
342. Murray G.I., et al. Matrix metal loproteinases and their inhibitors in gastric cancer. Gut. 43:1998;791-797.
343. Fielding J., et al. A randomized double-blind placebo-controlled study of Marimastat in patients with inoperable gastric adenocardnoma. ASCO Proc. 19:2000;240a-2400.
344. Talks K.L., Harris A.L. Current status of antiangiogenic factors. Br. J. Haematol. 109:2000;477-489.
345. Oehler M.K., Bicknell R. The promise of anti-angtogenic cancer therapy. Br. J. Cancer. 82:2000;749-752.
346. Takatsuka S., et al. Contribution of angiogenesis to the progression of colon cancer: possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis. Int. J. Oncol. 17:2000;253-258.
347. Bruns C.J., et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer. 89:2000;488-499.
348. Vitaliti A., et al. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res. 60:2000;4311-4314.
349. Motwani M., Delohery T.M., Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. 5:1999;1876-1883.
350. Zhu G.H., et al. Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-reiated genes. Dig. Dis. Sci. 44:1999;2020-2026.
351. Iseki H., et al. Cydin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery. 122:1997;187-194.
352. Wils J.A. Chemotherapy for gastrointestinal cancer new hopes or new disappointments. Scand. J. Gastroenterol. Suppl. 194:1992;87-94.
353. Yonemura Y., et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J. Surg. 19:1995;450-454.
354. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten. Ann. Oncol. 5:1994;8-11.
355. Thuss-Patience P.C., et al. Cisplatin/5FU (DDP/FU) as 2nd-line chemotherapy after CPT-11 (irinotecan) failure for patients with metastatic gastric carcinoma. Eur. J. Cancer. 4:(35 suppl.):1999;S149-S150.
356. Gunderson L.L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) dinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;1-11.
357. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur. J. Cancer. 35:1999;1963-1973.
358. Shimada K., Ajani J.A. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer. 86:1999;1657-1668.
359. Yao J.C., Shimada K., Ajani J.A. Adjuvant therapy for gastric carcinoma: dosing out the century. Oncology. 13:1999;1485-1494.
360. Use of thio-tepa as an adjuvant to the surgical management of carcinoma of the stomach. Cancer. 18:1965;291-297.
361. Longmire W.P. Jr, Kuzma J.W., Dixon W.J. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann. Surg. 167:1968;293-312.
362. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer. 49:1982;1116-1122.
363. Higgins G.A., et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 52:1983;1105-1112.
364. Imanaga H., Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J. Surg. 2:1977;213-221.
365. Alcobendas F., et al. Mitomycin C as an adjuvant in resected gastric cancer. Ann. Surg. 198:1983;13-17.
366. Inokuchi K., et al. Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer. 53:1984;2393-2397.
367. Hattori T., et al. Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. Jpn. J. Surg. 16:1986;175-180.
368. Kubota T., et al. Dose intensity of mitomycin C in adjuvant cancer chemotherapy for patients with gastric cancer. J. Surg.Oncol. 57:1994;40-45.
369. Niimoto M., et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futrafuf and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn. J. Surg. 18:1988;681-686.
370. Maehara Y., et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J. Surg. Oncol. 45:1990;169-172.
371. Hattori T., et al. Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or QK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn. J. Surg. 20:1990;127-136.
372. Nakazato H., et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer [see comments]. Lancet. 343:1994;1122-1126.
373. Sugimachi K., et al. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother. Pharmacol. 40:1997;233-238.
374. Grau J.J., et al. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J. Clin. Oncol. 16:1998;1036-1039.
375. Ducreux M., et al. Resected gastric carcinoma: Randomized trial of adjuvant chemotherapy with 5 FU-cisplatin (FUP). Final results of the FFCD 8801 trial. ASCO Proc. 19:2000;241a-2410.
376. Di Bartolomeo M., et al. Improved adjuvant therapy outcome in resected gastric cancer patients (Pts) according to node involvement 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. ASCO Proc. 19:2000;241a-2410.
377. Schlag P. Adjuvant chemotherapy in gastric cancer. World J. Surg. 11:1987;473-477.
378. Krook J.E., et al. A prospective randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer. 67:1991;2454-2458.
379. Chou F.F., et al. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J. Surg. Oncol. 57:1994;239-242.
380. Fujii M., et al. The optimal period for orally administered fluoropyrjmidines as an adjuvant chemotherapy for gastric cancer-a pilot study using 5-FU tablets compared with surgical operation alone. Gan. To. Kagaku. Ryoho. 21:1994;1199-1208.
381. Nakajima T., et al. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 2:1984;1366-1371.
382. Adjuvant treatments following curative resection for gastric cancer. Br. J. Surg. 75:1988;1100-1104.
383. Cirera L., et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J. Clin. Oncol. 17:1999;3810-3815.
384. Grau J.J., et al. Positive results of adjuvant mitomyoin-C in resected gastric cancer: a randomised trial on 134 patients. Eur. J. Cancer. 29A:1993;340-342.
385. Neri B., et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br. J. Cancer. 73:1996;549-552.
386. Nakajima T., et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 354:1999;273-277.
387. Allum W.H., Hallissey M.T., Kelly K.A. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1:1989;571-574.
388. Lise M., et al. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann. Surg. Oncol. 2:1995;495-501.
389. Hallissey M.T., et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: 5-year follow-up. Lancet. 343:1994;1309-1312.
390. Coombes R.C., et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol. 8:1990;1362-1369.
391. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;71-85.
392. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;1-15.
393. Casillas S., Pelley R.J., Milsom J.W. Adjuvant therapy for colorectal cancer: present and future perspectives. Dis. Colon. Rectum. 40:1997;977-992.
394. Hermans J., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11:1993;1441-1447.
395. Pignon J.P., Ducreux M., Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer, a critical reappraisal. J. Clin. Oncol. 12:1994;877-878.
396. Earle C.C., Marcun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer. 35:1999;1059-1064.
397. Mari E., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11:2000;837-843.
398. Oxman A.D., Clarke M.J., Stewart L.A. From science to practice. Meta-analyses using individual patient data are needed. J. Am. Med. Assoc. 274:1995;845-846.
399. Bleiberg H., et al. Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer. J. Clin. Oncol. 16:1998;3714.
400. Bruckner H.W., Stablein D.M. Sites of treatment failure: Gastrointestinal Tumor Study Group analysis of gastic, pancreatic, and colorectal trials. Cancer Treatment Symp. 2:1983;199-210.
401. Ajani J.A., et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J. Natl. Cancer Inst. 85:1993;1839-1844.
402. Ajani J.A., et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 68:1991;1501-1506.
403. Abe S., et al. Serosal invasion as the single prognostic indicator in stage IIIA (T3N1MO) gastric cancer. Surgery. 109:1991;582-588.
404. Esaki Y., Hirayama R., Hirokawa K. A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer. 65:1990;2086-2090.
405. Dupont J.B. Jr, et al. Adenocarcinoma of the stomach: review of 1497 cases. Cancer. 41:1978;941-947.
406. Yamada E., et al. The surgical treatment of cancer of the stomach. Int. Surg. 65:1980;387-399.
407. Pearlstone D.B., et al. Laparoscopy in 533 patients with abdominal malignancy. Surgery. 125:1999;67-72.
408. Nakajima T., et al. Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol. 22:1978;225-229.
409. Bozzetti R., Vaglini M., Deraco M. Intraperitoneal hyperthermic chemotherapy in gastric cancer:rationale for a new approach. Tumori. 84:1998;483-488.
410. Archer S., Gray B. Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases. Surgery. 108:1990;502-507.
411. Speyer J.L., et al. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 41:1981;1916-1922.
412. Shimoyama S., Shimizu N., Kaminishi M. Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J. Surg. 23:1999;284-291.
413. Atiq O.T., et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J. Clin. Oncol. 11:1993;425-433.
414. Crookes P., et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer. 79:1997;1767-1775.
415. Ikeguchi M., et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur. J. Surg. 161:1995;581-586.
416. Sayag A.C., et al. Intraoperative chemohyperthermia in the management of digestive cancers. A general review of literature. Oncology. 50:1993;333-337.
417. Barlogie B., Corry P.M., Drewinko B. In vitro thermochemotherapy of
418. Wallner K.E., Li G.C. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res. 47:1987;493-495.
419. Wallner K.E., De Gregorio M.W., Li G.C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res. 46:1986;6242-6245.
420. Yonemura Y., et al. A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterology. 46:1999;601-609.
421. Portilla A.G., Sugarbaker P.M., Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer analysis of prognostic features. World J. Surg. 23:1999;23-29.
422. Dedrick R.L., Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst. 89:1997;480-487.
423. Stephens A.D., et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann. Surg. Oncol. 6:1999;790-796.
424. Yu W., et al. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am. Surg. 64:1998;1104-1108.
425. Esquivel J., et al. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 113:1993;631-636.
426. Hagiwara A., et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 339:1992;629-631.
427. Rosen H.R., et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J. Clin. Oncol. 16:1998;2733-2738.
428. Yu W., et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann. Surg. 228:1998;347-354.
429. Sautner T., et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J. Clin. Oncol. 12:1994;970-974.
430. Hamazoe R., Maeta M., Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 73:1994;2048-2052.
431. Minsky B.D. The role of radiation therapy in gastric cancer. Semin. Oncol. 23:1996;390-396.
432. Budach V.G. The role of radiation therapy in the management of gastric cancer. Ann. Oncol. 5:(Suppl 3):1994;37-48.
433. Regine W.F., Mohiuddin M. Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;921-927.
434. Guzel Z., Gajl D., Grzegorzewski J. Postoperative radiotherapy in gastric cancer. J. Surg. Oncol. 58:1995;35-39.
435. Caudry M., et al. Radiotherapy of gastric cancer with a three field combination: feasibility, tolerance, and survival. Int. J. Radiat. Oncol. Biol. Phys. 13:1987;1821-1827.
436. Bleiberg H., et al. Hole of radiotherapy in cancers of the stomach. Bull. Cancer. 84:1997;913-916.
437. Bleiberg H., et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur. J. Surg. Oncol. 15:1989;535-543.
438. Mahadevan A., Carey D. The role of radiotherapy in the surgical management of gastrointestinal cancer. Surg. Oncol. 6:1997;201-208.
439. Klaassen D.J., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 3:1985;373-378.
440. Dent D.M., et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer. 44:1979;385-391.
441. Macdonald J.S., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Eng. J. Med. 345:(10):2001;725-730.
442. Vikram B. Radiotherapy for rectal cancer. New Eng. J. Med. 337:1997;347-348.
443. Heriot A.G., et al. Radiotherapy for rectal cancer. New Eng. J. Med. 337:1997;347-348.
444. Lavery I.C., Fazio V.W., Lopez-Kostner F. Radiotherapy for rectal cancer. New Eng. J. Med. 337:1997;346-347.
445. Bogden A.E., Moreau J.P., Eden P.A. Proliferate response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br. J. Cancer. 75:1997;1021-1027.
446. Abe M., Nishimura Y., Shibamoto Y. Intraoperative radiation therapy for gastric cancer. World J. Surg. 19:1995;544-547.
447. Abe M., et al. Clinical experiences with intraoperative radiotherapy of locally advanced cancers. Cancer. 45:1980;40-48.
448. Abe M., et al. Japan gastric trials in intraoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;1431-1433.
449. Abe M., et al. Intraoperative radiotherapy of gastric cancer. Cancer. 34:1974;2034-2041.
450. Hisamichi S. Screening for gastric cancer. World J. Surg. 13:1989;31-37.
451. Rich T.A. Intraoperative radiotherapy. Radiother. Oncol. 6:1986;207-221.
452. Martinez-Monge R., et al. Patterns of failure and long-term results in high-risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boost. J. Surg. Oncol. 66:1997;24-29.
453. Ogata T., et al. A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;341-347.
454. Avizonis V.N., et al. Treatment of adenocardnoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85-04. Ann. Surg. Oncol. 2:1995;295-302.
455. Coquard R., et al. Intraoperative radiation therapy combined with limited lymph node resection in gastric cancer an alternative to extended dissection. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;1093-1098.
456. Noyes R.D., et al. Surgical complications of intraoperative radiation therapy: the Radiation Therapy Oncology Group experience. J. Surg. Oncol. 50:1992;209-215.
457. de Villa V.H., et al. Arteriodigestive fistula: a complication associated with intraoperative and external beam radiotherapy following surgery for gastric cancer. J. Surg. Oncol. 49:1992;52-57.
458. Weese J.L., et al. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. Surgery. 128:2000;564-571.
459. Pelton J.J., et al. The influence of surgical margins on advanced cancer treated with intraoperative radiation therapy (IORT) and surgical resection. J. Surg. Oncol. 53:1993;30-35.
460. Abe M., et al. Intraoperative radiation therapy for carcinomas of the stomach and pancreas. Ann. Radiol. 32:1989;482-483.
461. Abe M., et al. Intraoperative radiotherapy in carcinoma of the stomach and pancreas. World J. Surg. 11:1987;459-464.
462. Viallet J., et al. A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. Cancer. 85:1999;2562-2569.
463. Pujol J.L., et al. Neoadjuvant etoposide, ifosfamide and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Chest. 115:1999;144-150.
464. Rougier P., et al. Advanced gastric cancer:Comparison of FAMTX (5FU, adriamycine, methotrexate) versus ELF (etoposide, 5 FU, leucovorin) versus FUP (infusional 5 FU+cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschafl für innere Onkologie (AIO). Eur. J. Cancer [A]. 31A:1995;S110-S116.
465. Allal A.S., et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility oncologic results and quality of life outcomes. Br. J. Cancer. 82:2000;1131-1137.
466. Janjan N.A., et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;1027-1038.
467. Murthy S.M., et al. The influence of surgical trauma on experimental metastasis. Cancer. 64:1989;2035-2044.
468. Aoki Y., et al. A model of port-site metastases of gallbladder cancer: the influence of peritoneal injury and its repair on abdominal wall metastases. Surgery. 125:1999;553-559.
469. Uchiyama A., et al. Hepatocyte growth factor and invasion-stimulatory activity are induced in pleurai fluid by surgery in lung cancer patients. Br. J. Cancer. 81:1999;721-726.
470. Bouvy N.D., et al. Laparoscopic surgery is associated with less tumour growth stimulation than conventional surgery: an experimental study. Br. J. Surg. 84:1997;358-361.
471. Nissen N.N., et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152:1998;1445-1452.
472. Howdieshell T.R., et al. Normoxic wound fluid contains high levels of vascular endothelial growth factor. Ann. Surg. 228:1998;707-715.
473. Kang M.A., et al. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J. Gene. Med. 2:2000;289-296.
474. Oku T., et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow fluorodeoxyglucose uptake and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58:1998;4185-4192.
475. Eggermont A.M., Steller E.P., Sugarbaker P.H. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery. 102:1987;71-78.
476. Fisher B., Gunduz N., Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 43:1983;1488-1492.
477. Gunduz N., Fisher B., Saffer E.A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 39:1979;3861-3865.
478. Holmgren L., O'Reilly M.S., Folkrnan J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153.
479. Hahnfeldt P., et al. Tumor development under angiogenic signaling; a dynamical theory of tumor growth, treatment response and postvascular dormancy. Cancer Res. 59:1999;4770-4775.
480. O'Reilly M.S., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
481. Folkman J. Angiogenesis inhibitors generated by tumors. Mol. Med. 1:1995;120-122.
482. Lemerle J., et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J. Clin. Oncol. 1:1983;604-609.
483. Shamberger R.C., et al. Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy. J. Pediatr. Surg. 26:1991;1113-1117.
484. Frykholm G.J., Glimelius B., Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis. Colon. Rectum. 36:1993;564-572.
485. Improved survival with preoperative radiotherapy in resectable rectal cancer. New Eng. J. Med. 336:1997;980-987.
486. Singletary S.E. Current treatment options for inflammatory breast cancer. Ann. Surg. Oncol. 6:1999;228-229.
487. Provisor A.J., et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. 15:1997;76-84.
488. Fink U., et al. Multimodal treatment for squamous cell esophageal cancer. World J. Surg. 19:1995;198-204.
489. Walsh T.N., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Eng. J. Med. 335:1996;462-467.
490. Nygaard K., et al. Pre-operative radiotherapy prolongs survival h operable esophageat carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J. Surg. 16:1992;1104-1109.
491. Basset J.F., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. New Eng. J. Med. 337:1997;161-167.
492. Law S., et al. Preoperative chemotherapy versus surgical therapy alone forsquamous cell carcinoma of the esophagus: a prospective randomized trial. J. Thorac. Cardiovasc. Surg. 114:1997;210-217.
493. Clark PI. Medical research council randomised trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus (MRC Upper Gl Tract Cancer Group). in Ann Oncol. 2000.
494. Braga M., et al. Food intake and nutritional status after total gastrectomy: results of a nutritional follow-up. Br. J. Surg. 75:1988;477-480.
495. Bragelmann R., et al. Nutrient malassimilation following total gastrectomy. Scand. J. Gastroenterol. Suppl. 218:1996;26-33.
496. Hebuterne X., et al. Correction of malnutrition following gastrectomy with cyclic enteral nutrition. Dig. Dis. Sci. 44:1999;1875-1882.
497. Hillman H.S. Postgastrectomy malnutrition. Gut. 9:1968;576-584.
498. Tovey F.I., Godfrey J.E., Lewin M.R. A gastrectomy population: 25-30 years on. Postgrad. Med. J. 66:1990;450-456.
499. Fink U., et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br. J. Surg. 82:1995;1248-1252.
500. Rougier P., et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur. J. Cancer. 30A:1994;1269-1275.
501. Kelsen D., et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisptatin plus intravenous fluorouracil. J. Clin. Oncol. 14:1996;1818-1828.
502. Leichman L., et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer a University of Southern California pilot program. J. Clin. Oncol. 10:1992;1933-1942.
503. Kelsen D.P., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. New Eng. J. Med. 339:1998;1979-1984.
504. Lowy A.M., et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg. 229:1999;303-308.
505. Otsuji E., et al. Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma. Ann. J. Gastroenterol. 94:1999;434-437.
506. Lowy A.M., et al. Laparoscopic staging for gastric cancer. Surgery. 119:1996;611-614.
507. Burke E.G., et al. Laparoscopy in the management of gastric adenocarcinorna. Ann. Surg. 225:1997;262-267.
508. Benevolo M., et al. Diagnostic and prognostic value of peritoneal immune-cytology in gastric cancer. J. Clin. Oncol. 16:1998;3406-3411.
509. Terashima M., et al. Sensitive detection of peritoneal micrometastasis in patients with gastric cancer. ASCO Proc. 19:2000;247a-2470.
510. Schneider P.M., et al. Histomorphologic regression grading and apoptotic-index as objective response parameters after neoadjuvant treatment for gastric cancer. AACR Proc. 41:2000;510-515.
511. Kang Y.K., et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. ASCO Proc. 15:1996;210-215.
512. Songun I., et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. Eur. J. Cancer. 35:1999;558-562.
513. Zhang Z.X., et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinorna of gastric cardia (AGC): Report on 370 patients. Int. J. Radiat. Oncol. Biol. Phys. 42:1998;929-934.
514. Shchepotin I.B., et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg. Oncol. 3:1994;37-44.